Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Evelo Biosciences price target lowered to $17 from $21 at BMO Capital » 08:39
07/02/20
07/02
08:39
07/02/20
08:39
EVLO

Evelo Biosciences

$4.90 /

-0.05 (-1.01%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini lowered the firm's price target on Evelo Biosciences to $17 from $21 to reflect the dilution from the company's recent follow-on offering. The analyst still keeps an Outperform rating on the shares and sees the interim results from the company's ongoing Phase 1/2 open-label trial of EDP1503 plus Keytruda as "early but encouraging" given its 33% objective response rate, supporting further enrollment to assess the potential of the drug.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$4.90 /

-0.05 (-1.01%)

EVLO Evelo Biosciences
$4.90 /

-0.05 (-1.01%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$4.90 /

-0.05 (-1.01%)

  • 25
    Jun
EVLO Evelo Biosciences
$4.90 /

-0.05 (-1.01%)

Wednesday
Hot Stocks
Evelo Biosciences to present data from Phase 1/2 trial of EDP1503 » 07:11
07/01/20
07/01
07:11
07/01/20
07:11
EVLO

Evelo Biosciences

$4.95 /

-0.21 (-4.07%)

Evelo Biosciences…

Evelo Biosciences announced that clinical data from the Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, in patients with advanced metastatic microsatellite stable colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors, will be presented at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting being held July 1 - 4, 2020. In addition to data in MSS CRC patients, the poster reported preliminary data on 11 TNBC patients. An overall response rate of 25% and a disease control rate of 37.5% were observed across all TNBC subjects receiving high dose EDP1503. ORR was 33% amongst response-evaluable patients on the high dose, with 2 patients awaiting first response assessment. Historic studies of anti-PD-1 monotherapy in heavily pretreated TNBC patients have yielded an ORR of 5-10%. The study continues enrollment in TNBC, and further data from this cohort will be available in 4Q 2020.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$4.95 /

-0.21 (-4.07%)

EVLO Evelo Biosciences
$4.95 /

-0.21 (-4.07%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$4.95 /

-0.21 (-4.07%)

  • 25
    Jun
EVLO Evelo Biosciences
$4.95 /

-0.21 (-4.07%)

Over a week ago
Syndicate
Evelo Biosciences 12M share Spot Secondary priced at $3.75 » 19:58
06/24/20
06/24
19:58
06/24/20
19:58
EVLO

Evelo Biosciences

$4.00 /

-0.22 (-5.21%)

The deal size was…

The deal size was increased to $45M from $40M and priced at low end of $3.75-$3.80 range. Morgan Stanley, Cowen and BMO Capital are acting as joint book running managers for the offering.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

  • 25
    Jun
EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

On The Fly
Fly Intel: After-Hours Movers » 19:06
06/24/20
06/24
19:06
06/24/20
19:06
FUL

H.B. Fuller

$41.02 /

-1.315 (-3.11%)

, ALLY

Ally Financial

$18.31 /

-1.09 (-5.62%)

, BDN

Brandywine Realty

$9.85 /

-0.545 (-5.24%)

, RPAI

Retail Properties of America

$6.41 /

-0.15 (-2.29%)

, TALO

Talos Energy

$9.17 /

-0.835 (-8.35%)

, XLRN

Acceleron

$102.41 /

-6.1 (-5.62%)

, YEXT

Yext

$16.56 /

-1.2 (-6.76%)

, KBH

KB Home

$33.38 /

-0.695 (-2.04%)

, QMCO

Quantum

$4.81 /

+0.41 (+9.32%)

, NG

NovaGold

$8.68 /

-0.08 (-0.91%)

, BB

BlackBerry

$4.92 /

-0.185 (-3.63%)

, QURE

uniQure

$62.85 /

-4.81 (-7.11%)

, XERS

Xeris Pharmaceuticals

$5.33 /

-0.15 (-2.74%)

, NK

NantKwest

$12.12 /

+0.35 (+2.97%)

, EVLO

Evelo Biosciences

$4.00 /

-0.22 (-5.21%)

, VSLR

Vivint Solar

$10.04 /

+0.03 (+0.30%)

, TBIO

Translate Bio

$26.73 /

+2.93 (+12.31%)

, SEDG

SolarEdge

$148.26 /

-3.32 (-2.19%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YEXT Yext
$16.56 /

-1.2 (-6.76%)

XLRN Acceleron
$102.41 /

-6.1 (-5.62%)

XERS Xeris Pharmaceuticals
$5.33 /

-0.15 (-2.74%)

VSLR Vivint Solar
$10.04 /

+0.03 (+0.30%)

TBIO Translate Bio
$26.73 /

+2.93 (+12.31%)

TALO Talos Energy
$9.17 /

-0.835 (-8.35%)

SEDG SolarEdge
$148.26 /

-3.32 (-2.19%)

RPAI Retail Properties of America
$6.41 /

-0.15 (-2.29%)

QURE uniQure
$62.85 /

-4.81 (-7.11%)

QMCO Quantum
$4.81 /

+0.41 (+9.32%)

NK NantKwest
$12.12 /

+0.35 (+2.97%)

NG NovaGold
$8.68 /

-0.08 (-0.91%)

KBH KB Home
$33.38 /

-0.695 (-2.04%)

FUL H.B. Fuller
$41.02 /

-1.315 (-3.11%)

EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

BDN Brandywine Realty
$9.85 /

-0.545 (-5.24%)

BB BlackBerry
$4.92 /

-0.185 (-3.63%)

ALLY Ally Financial
$18.31 /

-1.09 (-5.62%)

FUL H.B. Fuller
$41.02 /

-1.315 (-3.11%)

04/17/20 JPMorgan
H.B. Fuller upgraded to Overweight on longer-term potential at JPMorgan
04/17/20 JPMorgan
H.B. Fuller upgraded to Overweight from Neutral at JPMorgan
01/24/20 Citi
Citi upgrades H.B. Fuller to Neutral after management 'cleared the decks'
01/24/20 Citi
H.B. Fuller upgraded to Neutral from Sell at Citi
ALLY Ally Financial
$18.31 /

-1.09 (-5.62%)

06/11/20 Stephens
Ally Financial price target raised to $28 from $19 at Stephens
06/11/20 Citi
Ally Financial price target raised to $27 from $24 at Citi
06/05/20 Morgan Stanley
Ally Financial shares still have 'room to run,' says Morgan Stanley
06/03/20 Stephens
Stephens says Santander Consumer may benefit if Wells pulling back on auto loans
BDN Brandywine Realty
$9.85 /

-0.545 (-5.24%)

04/23/20 DA Davidson
Brandywine Realty price target lowered to $10.50 from $17 at DA Davidson
04/07/20 Citi
Brandywine Realty downgraded to Sell from Neutral at Citi
02/04/20 Mizuho
Brandywine Realty assumed with a Neutral at Mizuho
01/15/20
Fly Intel: Top five analyst downgrades
RPAI Retail Properties of America
$6.41 /

-0.15 (-2.29%)

04/22/20 JPMorgan
JPMorgan downgrades seven, upgrades one strip center REIT
04/22/20 JPMorgan
Retail Properties of America downgraded to Underweight from Neutral at JPMorgan
04/07/20 Citi
Retail Properties of America downgraded to Neutral from Buy at Citi
03/26/20 RBC Capital
Cheesecake, AMC news highlight tenants financial stress, says RBC Capital
TALO Talos Energy
$9.17 /

-0.835 (-8.35%)

06/24/20 MKM Partners
Talos Energy initiated with a Buy at MKM Partners
06/04/20
Fly Intel: Top five analyst initiations
06/04/20 BMO Capital
Talos Energy initiated with an Outperform at BMO Capital
04/24/20 Roth Capital
Talos Energy upgraded to Buy from Neutral at Roth Capital
XLRN Acceleron
$102.41 /

-6.1 (-5.62%)

05/26/20 Piper Sandler
Acceleron shares not pricing in PAH opportunity, says Piper Sandler
05/12/20 SVB Leerink
Acceleron price target raised to $127 from $104 at SVB Leerink
05/08/20 Credit Suisse
Acceleron price target raised to $123 from $99 at Credit Suisse
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
YEXT Yext
$16.56 /

-1.2 (-6.76%)

06/24/20 MKM Partners
Yext initiated with a Buy at MKM Partners
06/23/20 William Blair
Yext initiated with an Outperform at William Blair
06/10/20
Fly Intel: Top five analyst initiations
06/10/20 Needham
Yext initiated with a Buy at Needham
KBH KB Home
$33.38 /

-0.695 (-2.04%)

06/11/20 JPMorgan
PulteGroup upgraded, KB downgraded as JPMorgan adjusts homebuilder ratings
06/11/20 JPMorgan
KB Home downgraded to Underweight from Neutral at JPMorgan
06/09/20 RBC Capital
KB Home downgraded to Sector Perform from Outperform at RBC Capital
06/09/20 RBC Capital
KB Home downgraded to Sector Perform from Outperform at RBC Capital
QMCO Quantum
$4.81 /

+0.41 (+9.32%)

06/17/20 B. Riley FBR
Quantum credit amendments remove overhang, says B. Riley FBR
04/07/20 Lake Street
Quantum price target lowered to $5 from $8 at Lake Street
01/06/20 B. Riley FBR
Quantum price target raised to $9.50 from $7.15 at B. Riley FBR
12/30/19 Lake Street
Quantum's SEC settlement closes 'unpleasant' chapter, says Lake Street
NG NovaGold
$8.68 /

-0.08 (-0.91%)

BB BlackBerry
$4.92 /

-0.185 (-3.63%)

04/01/20 MKM Partners
BlackBerry price target lowered to $4.50 from $7.00 at MKM Partners
04/01/20 TD Securities
BlackBerry downgraded to Hold from Buy at TD Securities
11/04/19
Fly Intel: Top five analyst upgrades
11/04/19 BofA
BlackBerry upgraded to Neutral from Underperform at BofA/Merrill
QURE uniQure
$62.85 /

-4.81 (-7.11%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
XERS Xeris Pharmaceuticals
$5.33 /

-0.15 (-2.74%)

04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
02/18/20 Piper Sandler
Xeris Pharmaceuticals initiated with an Overweight at Piper Sandler
NK NantKwest
$12.12 /

+0.35 (+2.97%)

EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
VSLR Vivint Solar
$10.04 /

+0.03 (+0.30%)

06/24/20 Goldman Sachs
Vivint Solar downgraded to Neutral from Buy at Goldman Sachs
06/05/20 JMP Securities
Vivint Solar price target raised to $15 from $10 at JMP Securities
06/02/20 Roth Capital
Roth says loan securitizations reopening a positive for residential solar names
03/25/20 Roth Capital
ITC extension 'NOT' in Phase 3 coronavirus rescue package, says Roth Capital
TBIO Translate Bio
$26.73 /

+2.93 (+12.31%)

06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
06/23/20 Jefferies
Translate Bio price target raised to $29 from $17 at Jefferies
06/23/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
03/27/20 Roth Capital
Roth Capital highlights Translate Bio's scalable mRNA platform
SEDG SolarEdge
$148.26 /

-3.32 (-2.19%)

06/24/20 Goldman Sachs
SolarEdge downgraded to Sell from Neutral at Goldman Sachs
06/15/20 GLJ Research
Solar space earnings likely cut through remainder of 2020, says GLJ Research
06/04/20 GLJ Research
GLJ Research sees potential for SolarEdge margins to fall further through 2020
05/28/20 JPMorgan
SolarEdge price target raised to $166 from $131 at JPMorgan
YEXT Yext
$16.56 /

-1.2 (-6.76%)

XLRN Acceleron
$102.41 /

-6.1 (-5.62%)

XERS Xeris Pharmaceuticals
$5.33 /

-0.15 (-2.74%)

VSLR Vivint Solar
$10.04 /

+0.03 (+0.30%)

TBIO Translate Bio
$26.73 /

+2.93 (+12.31%)

TALO Talos Energy
$9.17 /

-0.835 (-8.35%)

SEDG SolarEdge
$148.26 /

-3.32 (-2.19%)

RPAI Retail Properties of America
$6.41 /

-0.15 (-2.29%)

QURE uniQure
$62.85 /

-4.81 (-7.11%)

QMCO Quantum
$4.81 /

+0.41 (+9.32%)

KBH KB Home
$33.38 /

-0.695 (-2.04%)

FUL H.B. Fuller
$41.02 /

-1.315 (-3.11%)

EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

BDN Brandywine Realty
$9.85 /

-0.545 (-5.24%)

BB BlackBerry
$4.92 /

-0.185 (-3.63%)

ALLY Ally Financial
$18.31 /

-1.09 (-5.62%)

  • 25
    Jun
  • 26
    Jun
  • 25
    Jun
  • 26
    Jun
VSLR Vivint Solar
$10.04 /

+0.03 (+0.30%)

QMCO Quantum
$4.81 /

+0.41 (+9.32%)

NK NantKwest
$12.12 /

+0.35 (+2.97%)

BB BlackBerry
$4.92 /

-0.185 (-3.63%)

YEXT Yext
$16.56 /

-1.2 (-6.76%)

XLRN Acceleron
$102.41 /

-6.1 (-5.62%)

XERS Xeris Pharmaceuticals
$5.33 /

-0.15 (-2.74%)

VSLR Vivint Solar
$10.04 /

+0.03 (+0.30%)

TBIO Translate Bio
$26.73 /

+2.93 (+12.31%)

SEDG SolarEdge
$148.26 /

-3.32 (-2.19%)

RPAI Retail Properties of America
$6.41 /

-0.15 (-2.29%)

NK NantKwest
$12.12 /

+0.35 (+2.97%)

KBH KB Home
$33.38 /

-0.695 (-2.04%)

EVLO Evelo Biosciences
$4.00 /

-0.22 (-5.21%)

BB BlackBerry
$4.92 /

-0.185 (-3.63%)

ALLY Ally Financial
$18.31 /

-1.09 (-5.62%)

VSLR Vivint Solar
$10.04 /

+0.03 (+0.30%)

TBIO Translate Bio
$26.73 /

+2.93 (+12.31%)

SEDG SolarEdge
$148.26 /

-3.32 (-2.19%)

QURE uniQure
$62.85 /

-4.81 (-7.11%)

QMCO Quantum
$4.81 /

+0.41 (+9.32%)

NK NantKwest
$12.12 /

+0.35 (+2.97%)

NG NovaGold
$8.68 /

-0.08 (-0.91%)

KBH KB Home
$33.38 /

-0.695 (-2.04%)

BB BlackBerry
$4.92 /

-0.185 (-3.63%)

ALLY Ally Financial
$18.31 /

-1.09 (-5.62%)

Syndicate
Evelo Biosciences files to sell $40M in common stock » 16:02
06/24/20
06/24
16:02
06/24/20
16:02
EVLO

Evelo Biosciences

$3.91 /

-0.31 (-7.35%)

Morgan Stanley, Cowen and…

Morgan Stanley, Cowen and BMO Capital Markets are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$3.91 /

-0.31 (-7.35%)

EVLO Evelo Biosciences
$3.91 /

-0.31 (-7.35%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$3.91 /

-0.31 (-7.35%)

EVLO Evelo Biosciences
$3.91 /

-0.31 (-7.35%)

On The Fly
Fly Intel: Pre-market Movers » 09:03
06/22/20
06/22
09:03
06/22/20
09:03
SPCE

Virgin Galactic

$14.98 /

-0.22 (-1.45%)

, EVOK

Evoke Pharma

$2.35 /

+0.07 (+3.07%)

, PCG

PG&E

$10.24 /

-0.585 (-5.41%)

, MYO

Myomo

$3.80 /

-0.05 (-1.30%)

, EVLO

Evelo Biosciences

$3.82 /

+0.17 (+4.66%)

, AAL

American Airlines

$16.00 /

-0.485 (-2.94%)

, TSN

Tyson Foods

$63.23 /

-0.75 (-1.17%)

, LK

Luckin Coffee

$3.82 /

-0.14 (-3.54%)

, NBRV

Nabriva Therapeutics

$0.81 /

-0.0554 (-6.37%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

MYO Myomo
$3.80 /

-0.05 (-1.30%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

EVOK Evoke Pharma
$2.35 /

+0.07 (+3.07%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

03/24/20 Morgan Stanley
Morgan Stanley upgrades Virgin Galactic to Overweight after over 70% drop
03/24/20 Morgan Stanley
Virgin Galactic upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/20 Morgan Stanley
Lead up to next lunar landings can have 'powerful impact,' says Morgan Stanley
02/27/20
Fly Intel: Top five analyst downgrades
EVOK Evoke Pharma
$2.35 /

+0.07 (+3.07%)

06/22/20 H.C. Wainwright
Evoke Pharma upgraded to Buy from Neutral at H.C. Wainwright
PCG PG&E
$10.24 /

-0.585 (-5.41%)

06/10/20 Barclays
PG&E price target raised to $16 from $15 at Barclays
06/09/20 Morgan Stanley
PG&E updated financing plan offers less downside risk, says Morgan Stanley
06/09/20 Mizuho
PG&E price target raised to $14.50 from $13.50 at Mizuho
06/05/20 BofA
PG&E resumed with a Buy at BofA
MYO Myomo
$3.80 /

-0.05 (-1.30%)

05/27/20
Myomo initiated with a Buy at Dougherty
03/23/20 Ascendiant
Myomo price target lowered to $15 from $45 at Ascendiant
11/14/19
Fly Intel: Top five analyst downgrades
11/14/19 Roth Capital
Roth Capital downgrades Myomo to Neutral, cuts target to 55c
EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
AAL American Airlines
$16.00 /

-0.485 (-2.94%)

06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

06/10/20 Credit Suisse
Tyson Foods price target raised to $75 from $70 at Credit Suisse
06/04/20
Fly Intel: Top five analyst upgrades
06/04/20 BofA
BofA cuts Pilgrim's Pride, Sanderson Farms targets after price fixing indictment
06/04/20 Bernstein
Tyson Foods upgraded to Outperform with $83 target at Bernstein
LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

04/08/20 GLJ Research
JinkoSolar price target lowered to $6.88 from $7.97 at GLJ Research
04/08/20 UBS
Starbucks price target lowered to $73 from $95 at UBS
04/06/20 MKM Partners
Starbucks price target raised to $60 from $52 at MKM Partners
04/02/20 KeyBanc
KeyBanc cuts Luckin Coffee to Sector Weight as company probes fake transactions
NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

06/22/20 Northland
Nabriva Therapeutics price target lowered to $1.50 from $2.50 at Northland
04/23/20 Northland
Nabriva Therapeutics price target lowered to $2.50 from $5 at Northland
04/09/20 H.C. Wainwright
Nabriva Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
04/08/20 Needham
Nabriva Therapeutics downgraded to Hold from Buy at Needham
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

MYO Myomo
$3.80 /

-0.05 (-1.30%)

EVOK Evoke Pharma
$2.35 /

+0.07 (+3.07%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

  • 23
    Jun
TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

TSN Tyson Foods
$63.23 /

-0.75 (-1.17%)

SPCE Virgin Galactic
$14.98 /

-0.22 (-1.45%)

PCG PG&E
$10.24 /

-0.585 (-5.41%)

NBRV Nabriva Therapeutics
$0.81 /

-0.0554 (-6.37%)

LK Luckin Coffee
$3.82 /

-0.14 (-3.54%)

AAL American Airlines
$16.00 /

-0.485 (-2.94%)

Hot Stocks
Evelo Biosciences advances EDP1815 to Phase 2/3 TACTIC-E COVID-19 Trial » 05:37
06/22/20
06/22
05:37
06/22/20
05:37
EVLO

Evelo Biosciences

$3.82 /

+0.17 (+4.66%)

Evelo Biosciences…

Evelo Biosciences announced that EDP1815 will be included in the TACTIC-E clinical trial. The trial will evaluate the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized patients at early stages of the disease. The trial's lead investigator is Dr. Joseph Cheriyan, Consultant Clinical Pharmacologist at Addenbrooke's Hospital in Cambridge, and is sponsored by Cambridge University Hospitals NHS Foundation Trust. Dr. Cheriyan said, "This is a critical time in the fight against COVID-19, and I am delighted that Cambridge is playing a key role in this. TACTIC-E will test the effectiveness of a number of experimental medicines in patients admitted to hospital, with a strong focus on identifying novel and clinically useful drugs early on. It will collect high quality data that can be used by our partner pharmaceutical companies to potentially seek approvals for widespread international use. We have opted to investigate EDP1815 in this trial given the tolerability and the modulation of multiple inflammatory pathways observed in a Phase 1b clinical trial for psoriasis. We look forward to evaluating EDP1815 as part of TACTIC-E." The company said in a release, "TACTIC-E is a Phase 2/3 randomised trial which will evaluate up to 469 patients per arm at Addenbrooke's Hospital and other leading UK clinical centres. The trial will enroll patients with COVID-19 who have identified risk factors for developing severe complications and are at risk of progression to the intensive care unit or death. Eligible patients will be randomised equally to either one of the active arms or treated with standard of care alone. Patients in arm 1 will be dosed with EDP1815 in addition to standard of care; patients in arm 2 will be dosed with a combination of ambrisentan and dapagliflozin in addition to standard of care; and patients in arm 3 will be treated with standard of care only. The primary outcome measure is a reduction in the number of patients who develop severe complications of organ failure, ventilation, or death. Secondary outcome measures include duration of stay in hospital, duration of oxygen therapy, changes in biomarkers associated with COVID-19 progression, and time to clinical improvement. Interim analyses will be performed over the course of the trial to evaluate results for signals of safety and efficacy. Interim data from the trial are anticipated during the fourth quarter of 2020. If the Phase 2/3 data are positive, Evelo plans to engage in discussions with global regulatory agencies to determine if the data support registration."

ShowHide Related Items >><<
EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

EVLO Evelo Biosciences
$3.82 /

+0.17 (+4.66%)

Over a month ago
Downgrade
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation » 07:48
05/21/20
05/21
07:48
05/21/20
07:48
EVLO

Evelo Biosciences

$4.20 /

-0.12 (-2.78%)

As previously reported,…

As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Evelo Biosciences to Equal Weight from Overweight with a price target of $8, down from $16. He removed atopic dermatitis from his model following the company's announcement during its recent earnings call that a newer formulation of EDP1815 is being evaluated in psoriasis and AD has been discontinued due to lack of efficacy. He maintains his view of the value of EDP1815 in psoriasis, and sees Phase 2 data in mid-2021 as the next key catalyst, Harrison added. He also noted that COVID-19 and TNBC data could present upside, but he has "modest expectations" for those data sets.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

Downgrade
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley » 05:20
05/21/20
05/21
05:20
05/21/20
05:20
EVLO

Evelo Biosciences

$4.20 /

-0.12 (-2.78%)

Morgan Stanley analyst…

Morgan Stanley analyst Matthew Harrison downgraded Evelo Biosciences to Equal Weight from Overweight with an $8 price target.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

EVLO Evelo Biosciences
$4.20 /

-0.12 (-2.78%)

Downgrade
Evelo Biosciences downgraded to Hold from Buy at Jefferies » 06:11
05/12/20
05/12
06:11
05/12/20
06:11
EVLO

Evelo Biosciences

$5.58 /

+0.5 (+9.84%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton downgraded Evelo Biosciences to Hold from Buy with a price target of $6, down from $18. The company's pipeline updates were more negative than positive as 2020 catalysts are now confined to the Phase 2 COVID-19 data and Phase 1/2 triple negative breast cancer by the end of 2020, Howerton tells investors in a research note. The analyst cautions investors on the potential for near-term dilution.

ShowHide Related Items >><<
EVLO Evelo Biosciences
$5.58 /

+0.5 (+9.84%)

EVLO Evelo Biosciences
$5.58 /

+0.5 (+9.84%)

EVLO Evelo Biosciences
$5.58 /

+0.5 (+9.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.